Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dominion Energy

Enbridge

Organon & Co., Enbridge, and Dominion Energy provide investors with above-average yields. Each stock's payout ratio seems manageable, with room for dividend payments to grow.

Want $5,000 in Annual Dividend Income? Invest in These 3 Stocks

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals.

Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals

Comerica

Newell Brands

Advance Auto Parts

Alaska Air Group

DXC Technology

Lincoln National

Sealed Air

Lower market values make companies vulnerable to being bounced from the key index.

Newell Brands, Comerica and Six Others That Could Be Dropped From the S&P 500

American Airlines

General Motors

NRG Energy

United Continental Hlds

Valero Energy

Viatris

Why deal with the S&P 500 when savings accounts pay 5%? That's exactly why many rich people are dumping stocks for cash.

9 S&P 500 Stocks Are Screaming Buys According To The 'Fed Model'

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women's Health.

Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women's Health

BorgWarner

CF Industries Holdings

JD.com

Leidos Hld

QUALCOMM

Investing is a tug-of-war between bullish and bearish sentiment. Near-term price swings provide long-term investors with great entry points to pick up unfairly beaten-down stocks.

7 Stocks That Are Long Overdue for a Relief Rally

Amgen

Bristol-Myers

Cigna

Centene

Gilead Sciences

Labcorp Holdings Inc

Pfizer

The stocks our screen found are cheap, relative to highfliers like Eli Lilly, and many are cheap for a reason.

9 Cheap Healthcare Stocks to Consider

The share price of Organon & Co. has taken a dramatic tumble after reporting quarters with sluggish revenue and earnings numbers. The dividend is holding at about a 5% yield and its safety seems of only slight concern because the company has strong cash flow.

Why Organon & Co. Is A Smart Investment

Organon & Co. (NYSE:OGN ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Conference Call Participants Unidentified Analyst - Evercore ISI Jason Gerberry - Bank of America Securities Navann Ty Dietschi - BNP Paribas Exane David Amsellem - Piper Sandler Gregory Fraser - Truist Securities Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon First Quarter 2023 Earnings Conference Call.

Organon & Co (OGN) Q1 2023 Earnings Call Transcript

Organon (OGN) came out with quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.65 per share a year ago.

Organon (OGN) Lags Q1 Earnings Estimates

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Results for the First Quarter Ended March 31, 2023.

Organon Reports Results for the First Quarter Ended March 31, 2023

Organon To Report First Quarter and Host Conference Call on May 4, 2023

Abbott Labs

Elevance Health Inc

UnitedHealth Group

Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.

8 Defensive Plays as Healthcare Stocks Stumble

Citizens Financial Group

Fifth Third Bancorp

Hasbro

Iron Mountain

Realty Income Corp

Healthpeak Properties

Philip Morris

Vici Properties

During a period of high interest rates, it might be more difficult to impress investors with dividend stocks. But the stocks can have an important advantage over the long term.

10 dividend stocks yielding at least 4.5% that are rated ‘buy' by most analysts

Lowe's

Halliburton

Hudbay Minerals

United Rentals

It's too early to say the market has turned the corner, but some analysts suggest that equities could be at the beginning of a bull market. The banking crisis appears to be contained.

7 Growth Stocks That Are Trading at a Bargain Price

Organon & Co. has seen mostly margin disappointments since the spinoff from Merck & Co., Inc. While the performance is not comforting, valuations are non-demanding.

Organon: A Bitter Pill

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. ("Organon" or the "Company") (NYSE:  OGN).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Building on Organon's Prior FP2030 Commitment, the Company Announces $30 Million in New Funding to Fuel Global Action and Community-Driven Solutions Needed by the 121 Million Women and Girls Who Experience Unplanned Pregnancies Each Year

Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist

Energy Transfer LP Unit

Fresenius Medical Care

Taro Pharmaceutical Industries

Teva Pharmaceutical

Francisco Garcia Parames' Cobas Funds 4th-Quater Letter

The company reported fourth-quarter and year-end financials.

Why Shares of Organon Fell 15% Thursday

Organon & Co (NYSE:OGN ) Q4 2022 Earnings Conference Call February 16, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Terence Flynn - Morgan Stanley Umer Raffat - Evercore ISI Navann Ty - BNP Paribas Exane Gregory Fraser - Truist Securities Stephen Scala - Cowen and Company Christopher Schott - JPMorgan Chase & Co. David Amsellem - Piper Sandler & Co. Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon Fourth Quarter and Full Year 2022 Earnings Conference Call.

Organon & Co (OGN) Q4 2022 Earnings Call Transcript

Organon (OGN) delivered earnings and revenue surprises of -4.71% and 1.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Q4 Earnings and Revenues Miss Estimates

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2022. "We enter 2023 with momentum, building off the significant achievements in our short history as an independent company," said Kevin Ali, Organon's CEO.

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022

AbbVie

Alvotech SA

Coherus BioSciences

CVS Health

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Competition Coming For AbbVie's Blockbuster Humira

News for Organon & Co Stock (OGN)